ISSN: 2634 - 680X

Journal of Clinical Case Studies Reviews & Reports

SCIENTIFIC Research and Community

Review Article

Open Access

Neuropsychiatric Manifestation of HMPV: A Review

Arockia Philip Raj A[1]* and Mostafa Abdel Monem Amr[2]

[1]Assistant Professor, Department of Psychiatry and Behavioral Sciences, College of Medicine and Health Sciences, National University of Science and technology, Oman

[2]Head of the Department, Department of Psychiatry and Behavioral Sciences, College of Medicine and Health Sciences, National University of Science and technology, Oman & Visiting professor, Dept of Psychiatry, Mansoura University, Egypt

ABSTRACT

Human metapneumovirus (HMPV) is a significant respiratory pathogen with emerging evidence linking it to neuropsychiatric complications. While primarily causing upper and lower respiratory infections in young children, the elderly, and immunocompromised individuals, HMPV's neuropsychiatric manifestations, including encephalitis, seizures, and cognitive impairments, are increasingly recognized. The virus's ability to incite neuroinflammation, disrupt the blood-brain barrier, and elicit robust cytokine responses (e.g., IL-6, TNF-α, IFN-γ) underlies its potential to contribute to neurological and psychiatric symptoms. Vulnerable populations, such as children, neonates, and immunocompromised adults, are particularly at risk of acute and long-term effects, including mood disturbances, attention deficits, and neurodevelopmental delays. Age-related immune changes may further exacerbate these complications, highlighting the need for early detection, targeted antiviral therapies, and preventive strategies. This review underscores the importance of understanding HMPV's systemic impact to mitigate its neuropsychiatric sequelae and develop effective interventions for affected populations.

***Corresponding author**

Arockia Philip Raj A, Assistant Professor, Department of Psychiatry and Behavioral Sciences, College of Medicine and Health Sciences, National University of Science and technology, Oman.

Received: January 16, 2025; **Accepted:** January 21, 2025; **Published:** January 30, 2025

Epidemiological Insights

Human metapneumovirus (HMPV) is a significant respiratory pathogen causing upper and lower respiratory tract infections, particularly in young children, the elderly, and immunocompromised individuals [1]. The HMPV fusion (F) protein is unique among paramyxoviruses, as it mediates both attachment and fusion without a separate attachment protein. HMPV infections peak during late winter and early spring, coinciding with other respiratory viruses like RSV and influenza. It occurs early in life, with nearly all children infected by age 5, but re-infections are common throughout adulthood [2].

Emerging epidemiological trends suggest that neuropsychiatric complications associated with HMPV may be more frequent in populations with pre-existing neurological or psychiatric disorders. These groups may experience exacerbation of symptoms or increased vulnerability to infection-related cognitive and mood disturbances.

Pathophysiological Mechanisms

HMPV's interaction with the host immune system is a critical area of investigation as a causal factor particularly regarding its potential to incite neuroinflammation. The virus is known to elicit a robust cytokine response, with elevated levels of pro-inflammatory markers like IL-6, TNF-α, and IFN-γ. These cytokines can cross the blood-brain barrier, leading to microglial activation within the CNS, a process strongly implicated in central nervous system (CNS) inflammation and potentially contributing to neuropsychiatric symptoms [3].

Additionally, studies highlight the potential role of viral persistence in perpetuating neurological damage. Evidence suggests that HMPV can disrupt the blood-brain barrier integrity, allowing immune mediators and potentially viral components to interact with neural tissues. This disruption may lead to astrocytic dysfunction, synaptic impairment, and, ultimately, neurological symptoms [4].

Moreover, the role of interferons, particularly IFN-λ, has been highlighted in modulating the immune response during HMPV infection. IFN-λ has been shown to promote antiviral responses in the lungs without inducing significant immunopathology, suggesting its potential as a therapeutic target for treating HMPV infections [5]. Age-related changes in immune response, as seen in older adults, may compound the neuroinflammatory effects of HMPV. Reduced production of antiviral interferons and a shift toward Th2-dominated immune responses have been noted, leading to prolonged viral clearance and increased susceptibility to CNS damage [6].

Understanding these complex interactions between HMPV and the host immune system is crucial for developing effective treatments and preventive strategies against the virus's neuropsychiatric and systemic effects.

Neuropsychiatric Manifestations

While HMPV is primarily associated with respiratory infections, emerging evidence highlights its potential systemic impact, including neuropsychiatric sequelae like encephalitis, seizures, and cognitive dysfunction, which have been reported in isolated cases of HMPV infection [7].

Preliminary case reports and small cohort studies suggest an association between HMPV and acute encephalopathy, characterized by altered mental status, seizures, or focal neurological deficits. These manifestations are hypothesized to result from direct viral invasion or an exaggerated immune response. Furthermore, neuroinflammatory pathways activated by HMPV may overlap with those seen in other viral infections, such as influenza and RSV, which are known to cause encephalitis [8].

Additionally, there is limited but growing evidence suggesting long-term neuropsychiatric effects post-HMPV infection, particularly in vulnerable populations such as children and the elderly. Cognitive impairments, mood disturbances, and neurodevelopmental delays have been speculated in post-viral syndromes, though robust epidemiological data are lacking.

This highlights the need for further research into the neuropsychiatric spectrum of HMPV, with a focus on identifying specific biomarkers and risk factors for these complications.

Neuropsychiatric Complications of Human Metapneumovirus (HMPV)

Human metapneumovirus (HMPV) is not only a significant respiratory pathogen but has also been associated with various neuropsychiatric complications. These complications can manifest differently in neonates and children compared to adults, particularly those who are immunocompromised.

Neonates and Children

In neonates and young children, HMPV infection can lead to neuropsychiatric manifestations. Following HMPV infection, some children may directly exhibit neurological symptoms such as seizures, altered mental status, and irritability [9]. Also, some children may experience psychiatric symptoms, including increased anxiety, attention deficits, and mood disorders. These changes may be linked to the neuroinflammatory processes triggered by the viral infection. The long-term neurodevelopmental impact of HMPV in children is an area of ongoing research [10]. Studies are needed to determine the extent of any lasting neuropsychiatric effects and how they may manifest as difficulties in cognitive, motor, and social skills as the child grows

Adults who are Immunocompromised

For adults, particularly those who are immunocompromised, HMPV infection can lead to more severe neuropsychiatric complications. The immediate aftermath of the infection immunocompromised individuals are at a higher risk of developing acute encephalitis following HMPV infection [11]. This condition can lead to significant neurological deficits and may require intensive medical intervention. In the long run there is a potential for cognitive impairment in adults recovering from HMPV infections, especially among those with weakened immune systems. Cognitive deficits may manifest as problems with memory, attention, and executive function. The stress of dealing with a severe respiratory illness, combined with the neuroinflammatory response, can contribute to multiple psychiatric manifestations. Adults may experience exacerbation of pre-existing psychiatric conditions, such as depression and anxiety, or new episodes of mood disorders and anxiety disorders following HMPV infection [12].

Long-term studies suggest that adults who have experienced severe respiratory infections may have an increased risk of developing neurodegenerative conditions, such as dementia, later in life. Research indicates that ongoing inflammation and immune system dysregulation may play a crucial role in the progression of these neurological disorders.

Future Guidelines for Research and Review

The prevention of neuropsychiatric complications associated with Human Metapneumovirus (hMPV) requires a multifaceted approach that addresses both immediate clinical management and long-term strategies. Given the evidence of hMPV's potential to cause neurological alterations, it is crucial to implement guidelines that focus on early detection, effective treatment, and public health measures.

Early Detection and Screening

Regular screening for neurological symptoms in patients with hMPV, especially in vulnerable populations such as children and immunocompromised individuals, can facilitate early intervention [13]. Implementing cognitive assessments post-infection can help identify long-term neuropsychiatric effects, similar to strategies used for other viral infections like SARS-CoV-2 [14]. Given the high prevalence of HMPV in children and immunocompromised adults increased focus on these subgroups on early detection and screening would give a positive outcome. Explore potential co-infections with SARS-CoV-2 and their compounded neuropsychiatric impact.

Treatment Protocols

Development of antiviral therapies that specifically address the neuroinflammatory responses associated with hMPV could mitigate neurological complications [15]. Providing comprehensive supportive care, including psychological support and rehabilitation, is essential for patients recovering from hMPV-related encephalopathy [16].

Public Health Initiatives

Promoting vaccination against hMPV and increasing public awareness about its potential neuropsychiatric effects can help reduce incidence rates [17]. Increased funding for research into the neuropsychiatric impacts of hMPV will enhance understanding and inform future prevention strategies.

While these guidelines focus on prevention, it is also important to consider that some neuropsychiatric symptoms may arise from the broader context of viral infections, including environmental stressors and immune responses, which can complicate the clinical picture [18].

Conclusion

The neuropsychiatric complications associated with HMPV infection highlight the need for comprehensive monitoring and management strategies in affected populations, particularly in neonates, children, and immunocompromised adults. Understanding the complex interplay between respiratory infections and neurological health is essential, as it may lead to innovative approaches in both treatment and prevention for at-risk populations. As we move forward, it is imperative to develop comprehensive prevention strategies and intervention protocols that address these multifaceted challenges, ensuring the well-being of affected individuals across all age groups.

References

1. S. Panda, N. K. Mohakud, L. Pena, and S. Kumar, "Human metapneumovirus: review of an important respiratory pathogen," Int. J. Infect. Dis. IJID Off. Publ. Int. Soc. Infect. Dis., vol. 25, pp. 45–52, Aug. 2014, doi: 10.1016/j.ijid.2014.03.1394.
2. V. Schildgen et al., "Human Metapneumovirus: lessons learned over the first decade," Clin. Microbiol. Rev., vol. 24, no. 4, pp. 734–754, Oct. 2011, doi: 10.1128/CMR.00015-11.

3. A. Vehapoglu, O. Turel, T. Uygur Sahin, N. O. Kutlu, and A. Iscan, "Clinical Significance of Human Metapneumovirus in Refractory Status Epilepticus and Encephalitis: Case Report and Review of the Literature," Case Rep. Neurol. Med., vol. 2015, p. 131780, 2015, doi: 10.1155/2015/131780.
4. J. A. Soto et al., "Human Metapneumovirus: Mechanisms and Molecular Targets Used by the Virus to Avoid the Immune System," Front. Immunol., vol. 9, p. 2466, 2018, doi: 10.3389/fimmu.2018.02466.
5. J. Sepúlveda-Alfaro et al., "Human metapneumovirus respiratory infection affects both innate and adaptive intestinal immunity," Front. Immunol., vol. 15, p. 1330209, 2024, doi: 10.3389/fimmu.2024.1330209.
6. J. Sojati et al., "IFN-λ drives distinct lung immune landscape changes and antiviral responses in human metapneumovirus infection," mBio, vol. 15, no. 5, p. e0055024, May 2024, doi: 10.1128/mbio.00550-24.
7. P. J. Busse and S. K. Mathur, "Age-related changes in immune function: effect on airway inflammation," J. Allergy Clin. Immunol., vol. 126, no. 4, pp. 690–699; quiz 700–701, Oct. 2010, doi: 10.1016/j.jaci.2010.08.011.
8. [8] K. Bohmwald, N. M. S. Gálvez, M. Ríos, and A. M. Kalergis, "Neurologic Alterations Due to Respiratory Virus Infections," Front. Cell. Neurosci., vol. 12, p. 386, Oct. 2018, doi: 10.3389/fncel.2018.00386.
9. O. Schildgen et al., "Human metapneumovirus RNA in encephalitis patient," Emerg. Infect. Dis., vol. 11, no. 3, pp. 467–470, Mar. 2005, doi: 10.3201/eid1103.040676.
10. T. Heikkinen, R. Osterback, V. Peltola, T. Jartti, and R. Vainionpää, "Human metapneumovirus infections in children," Emerg. Infect. Dis., vol. 14, no. 1, pp. 101–106, Jan. 2008, doi: 10.3201/eid1401.070251.
11. A. R. Falsey, D. Erdman, L. J. Anderson, and E. E. Walsh, "Human Metapneumovirus Infections in Young and Elderly Adults," J. Infect. Dis., vol. 187, no. 5, pp. 785–790, Mar. 2003, doi: 10.1086/367901.
12. L. E. M. Haas, S. F. T. Thijsen, L. van Elden, and K. A. Heemstra, "Human metapneumovirus in adults," Viruses, vol. 5, no. 1, pp. 87–110, Jan. 2013, doi: 10.3390/v5010087.
13. N. Akhras, J. B. Weinberg, and D. Newton, "Human metapneumovirus and respiratory syncytial virus: subtle differences but comparable severity," Infect. Dis. Rep., vol. 2, no. 2, p. e12, Aug. 2010, doi: 10.4081/idr.2010.e12.
14. J. B. Fanshawe et al., "Cognitive domains affected post-COVID-19; a systematic review and meta-analysis," Eur. J. Neurol., vol. 32, no. 1, p. e16181, Jan. 2025, doi: 10.1111/ene.16181.
15. H. C. Bergeron, J. Crabtree, T. Nagy, D. E. Martin, and R. A. Tripp, "Probenecid Inhibits Human Metapneumovirus (HMPV) Replication In Vitro and in BALB/c Mice," Viruses, vol. 16, no. 7, p. 1087, Jul. 2024, doi: 10.3390/v16071087.
16. J. C. Arnold et al., "Human Metapneumovirus Associated With Central Nervous System Infection in Children," Pediatr. Infect. Dis. J., vol. 28, no. 12, pp. 1057–1060, Dec. 2009, doi: 10.1097/INF.0b013e3181acd221.
17. J. Ren, T. Phan, and X. Bao, "Recent vaccine development for human metapneumovirus," J. Gen. Virol., vol. 96, no. Pt 7, pp. 1515–1520, Jul. 2015, doi: 10.1099/vir.0.000083.
18. P. Büttiker et al., "HIV, HSV, SARS-CoV-2 and Ebola Share Long-Term Neuropsychiatric Sequelae," Neuropsychiatr. Dis. Treat., vol. Volume 18, pp. 2229–2237, Oct. 2022, doi: 10.2147/NDT.S382308.